{"filings":[{"id":554724,"accession_number":"0001104659-26-064514","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2026-05-20T20:15:21+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Annovis Bio prices $15M public offering of 7.9M shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 7,895,000 shares and warrants for 7,105,500 shares at combined price $1.90.","Gross proceeds of ~$15M; expected closing May 21, 2026.","Warrants exercisable at $2.25 per share, six-year term from issuance.","Net proceeds for clinical development of buntanetap in Alzheimer's and Parkinson's and working capital.","Canaccord Genuity acting as sole bookrunner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":470317,"accession_number":"0001104659-26-062451","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2026-05-15T20:00:58+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annovis Bio Q1 net loss $0.63/sh; AD Phase 3 85% enrolled; NDA planned early 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share $0.63 (vs $0.32 in Q1 2025); R&D spend $16.7M (up from $5.0M).","Cash $14.2M at Mar 31, 2026; $10M April offering not included; 28.5M shares outstanding.","Phase 3 AD trial 85% enrolled, full enrollment on track summer 2026; DSMB safety recommendation positive.","PD OLE study 40% enrolled; NDA for buntanetap symptomatic AD treatment expected early 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93081,"accession_number":"0001104659-26-041584","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Annovis Bio prices $10M underwritten offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pricing of 5,263,156 shares and 5,263,156 warrants at $1.90 per unit, gross proceeds ~$10M.","Warrants exercisable at $2.50/share, beginning 6 months after issuance, expiring 5.5 years from issue.","Net proceeds to fund continued clinical development of buntanetap in Phase 3 Alzheimer's study and for working capital.","Offering expected to close on April 10, 2026; Canaccord Genuity sole bookrunner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104415,"accession_number":"0001104659-26-034611","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Annovis Bio CFO Mark Guerin departs; CEO Maria Maccecchini appointed acting CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Guerin left as CFO effective March 23, 2026; departure unrelated to any disagreement with the company.","CEO Maria Maccecchini will serve as Acting CFO until a permanent replacement is identified.","No financial impact disclosed; company continues operations with existing management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104414,"accession_number":"0001104659-26-028574","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annovis Bio reports FY2025 net loss $1.40/sh; Phase 3 AD trial 65% enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 net loss $1.40 basic and diluted EPS; R&D $25.2M, G&A $4.5M; cash $19.5M expected to fund into Q3 2026.","Phase 3 AD trial (NCT06709014) 65% enrolled across 83 US sites; DSMB positive recommendation at 6-month safety review.","Open-label extension PD study initiated Jan 2026; FDA positive recommendation for PD dementia study design discussions.","All patents transferred to new crystal form of buntanetap, extending IP protection to 2047.","Appointed Mark Guerin as CFO and Hui Liu as Director of Biostatistics in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104413,"accession_number":"0001104659-26-013948","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Annovis Bio receives DSMB approval to continue Phase 3 Alzheimer's trial of buntanetap","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DSMB issued positive recommendation on buntanetap safety at 6 months; trial continues without modification.","Phase 3 AD trial is 40% complete; first symptomatic efficacy readout expected in early 2027.","FDA indicated it may accept combined safety data from Alzheimer's and Parkinson's studies in future NDA submission.","6-month safety data in Alzheimer's patients consistent with those observed in Parkinson's patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104412,"accession_number":"0001104659-26-007423","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Annovis Bio holds webinar Jan 28, 2026; no clinical or financial data furnished","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company conducted a webinar with CEO Maria Maccecchini; no new results or data disclosed in filing.","Exhibit 99 contains only a title slide and standard forward-looking statement, no financial or clinical details.","No guidance, trial updates, or material business developments were provided in the 8-K exhibit.","Filing is procedural Regulation FD disclosure for the webinar event itself, not a substantive update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120705,"accession_number":"0001104659-25-110548","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annovis Bio reports Q3 net loss of $0.37/share; Phase 3 AD trial fully activated at 84 sites","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $15.3M as of Sep 30, 2025; plus $9.4M in Oct offerings.","Phase 3 early AD study (NCT06709014) fully activated; first patients completed 6-month treatment.","Biomarker results from Phase 2/3 showed reductions in neuroinflammation and neurodegeneration markers.","Appointed Mark Guerin as CFO; all patents transferred to new crystal form of buntanetap (IP through 2046).","R&D expense $6.3M (up from $2.7M YoY); net loss $0.37 per share (vs $0.97)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120704,"accession_number":"0001104659-25-103254","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Annovis Bio raises ~$3.4M in offering of 1.67M shares at $2.05 for Alzheimer's trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1,670,732 shares at $2.05 each; gross proceeds ~$3.425M before expenses.","Two board members purchase 1,073,171 shares under separate subscription agreements.","Net proceeds to fund Phase 3 study of Buntanetap for Alzheimer's disease and working capital.","Placement agent H.C. Wainwright receives 7% cash fee and warrants for 83,537 shares at $2.5625.","Closing expected October 28, 2025; lock-up on further issuance until November 28, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120703,"accession_number":"0001104659-25-099356","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Annovis Bio raises ~$6M in registered direct offering of 4M shares/pre-funded warrants at $1.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering comprises 3.15M shares and 850K pre-funded warrants at $1.50 per share (warrant price $1.4999); gross proceeds ~$6M.","Net proceeds to fund Phase 3 study of Buntanetap for Alzheimer's disease, working capital, and general corporate purposes.","H.C. Wainwright acts as exclusive placement agent; 7% cash fee plus 200K warrants exercisable at $2.20 per share for 5 years.","Officers and directors subject to 45-day lock-up from closing date, which is expected on or about October 13-14, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137298,"accession_number":"0001104659-25-094522","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Annovis Bio appoints Mark Guerin as CFO; base salary $450K plus options for 200K shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Guerin appointed CFO effective Sept 25, 2025; previously CFO of Onconova/Traws Pharma (TRAW).","Compensation: $450K base salary, 40% annual target bonus, options for 200,000 shares, six months severance.","Guerin holds CPA, CMA, CFM certifications; began career at Coopers & Lybrand.","No transactions requiring disclosure under Item 404(a) between Guerin and the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137297,"accession_number":"0001104659-25-079248","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Annovis Bio CFO resigns; CEO Maccecchini appointed acting CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Walsh resigned as VP of Finance and Principal Financial Officer, effective Aug 22, 2025.","Resignation was not due to any disagreement with the company's operations, policies, or practices.","CEO Maria Maccecchini appointed Acting CFO effective Aug 15, 2025, by unanimous board vote.","Company has begun actively searching for a permanent Chief Financial Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137296,"accession_number":"0001104659-25-076851","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annovis Bio Q2 net loss $0.32/sh; cash $17.1M; Phase 3 AD trial advances with 38 patients randomized","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $17.1M as of June 30, 2025, up from $10.6M at Dec 31, 2024.","Net loss per share $0.32 (basic/diluted) for Q2 2025 vs $0.44 in Q2 2024.","Phase 3 early AD trial: 38 patients randomized, nearly 200 in screening, 76 U.S. sites (46 enrolling).","R&D expenses $5.2M, G&A $1.1M, both down YoY.","Transferred all patent families to crystal buntanetap, achieving comprehensive global IP coverage."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154610,"accession_number":"0001104659-25-061751","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Annovis Bio stockholders elect all five director nominees and ratify Ernst & Young as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["11,588,981 shares (59.47% of outstanding) represented at June 17, 2025 annual meeting.","Directors Maccecchini, Hoffman, Bruck, McCarthy, White elected; broker non-votes ~7.2M each.","Ratification of Ernst & Young LLP as independent auditor passed with 11,382,542 votes for.","Auditor ratification had 187,959 against and 18,480 abstain; no other proposals voted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154609,"accession_number":"0001104659-25-060784","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NYSE accepts Annovis Bio's plan to regain listing compliance; 18-month cure period","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Annovis received NYSE acceptance of its plan to regain compliance with minimum market capitalization and stockholders' equity standards.","NYSE granted an 18-month period from March 26, 2025, to achieve compliance; stock remains listed subject to plan adherence.","Annovis must provide quarterly progress updates to NYSE; business operations and SEC reporting unaffected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154608,"accession_number":"0001104659-25-047871","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Annovis Bio starts Phase 3 Alzheimer's trial, reports Q1 net loss $0.32 per share, cash $22.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["First participants entered pivotal Phase 3 AD trial on Feb 5, 2025; planning 760 participants, evaluating buntanetap.","Cash and equivalents $22.2M as of Mar 31, 2025 (vs $10.6M a year ago).","R&D expenses $5.0M in Q1 2025 vs $6.5M Q1 2024; G&A flat at $1.3M.","Net loss per share $0.32 basic/diluted for Q1 2025 vs $0.10 basic and $0.72 diluted in Q1 2024.","Appointed Andrew Walsh (VP Finance) as Principal Financial Officer; salary $264,000 + 25% target bonus."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173141,"accession_number":"0001104659-25-028803","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["3.01","5.02","7.01","9.01"],"status":"ready","headline":"Annovis Bio receives NYSE delisting notice, market cap ~$37.9M, equity $9.3M; CFO Fricker departs","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NYSE notice: 30-day avg mkt cap ~$37.9M, equity $9.3M at Dec 31, 2024, both below $50M thresholds.","Company has 45 days to submit compliance plan; NYSE may grant up to 18-month cure period; symbol gets '.BC' indicator.","No immediate impact on stock listing, business operations, or SEC reporting obligations.","Interim CFO William Fricker departs March 27 by mutual agreement; no dispute over accounting.","CEO Maria Maccecchini assumes interim principal financial officer role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173140,"accession_number":"0001104659-25-026714","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annovis Bio reports Q4/FY2024 results; launches Phase 3 AD trial with data expected mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $0.43/share vs $2.24 YoY; FY net loss $2.02 basic, $2.31 diluted vs $6.23 in 2023.","Cash $10.6M at Dec 31, 2024; after $21M stock offering, runway extends to Q4 2025.","Phase 3 early AD trial launched Feb 2025; symptomatic data expected mid-2026, disease-modifying data mid-2027.","FDA cleared Phase 3 early AD trial Oct 2024 based on Phase 2/3 data showing symptomatic improvement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173139,"accession_number":"0001104659-25-009387","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Annovis Bio enters first patients into pivotal Phase 3 Alzheimer's study of buntanetap","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First two patients enrolled in pivotal Phase 3 trial of buntanetap for early Alzheimer's disease.","Trial is 18-month, randomized, placebo-controlled, double-blind with primary endpoints ADAS-Cog13 and ADCS-iADL.","Over 750 participants expected across ~100 US sites; FDA-approved protocol.","Company raised $21M gross from public offering of 5.25M units to fund initial 6 months; 12-month from warrant exercises.","CEO cites prior Phase 2/3 data showing cognitive improvement and no safety concerns."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173138,"accession_number":"0001104659-25-009279","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Annovis Bio closes $21M public offering of 5.25M units with warrants at $4.00/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 5,250,000 units (1 share + 1 warrant) at $4.00 per unit; gross proceeds $21M.","Warrants exercisable at $5.00 per share, immediately exercisable, 5-year term.","Net proceeds to fund Phase 3 study of Buntanetap for Alzheimer's disease and working capital.","Offering closed on February 4, 2025; underwritten by ThinkEquity LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190164,"accession_number":"0001104659-24-127626","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Annovis Bio presents investor deck on path to NDA for Alzheimer's and Parkinson's","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation on December 11, 2024 outlines development path to NDA for Alzheimer's and Parkinson's.","Deck used during live webcast; full content not available in this filing excerpt.","No specific clinical data, financial figures, or milestone dates disclosed in the provided text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190163,"accession_number":"0001104659-24-127439","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Annovis Bio enters $50M at-the-market equity distribution agreement with Oppenheimer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement allows sale of up to $50M of common stock at-the-market through Oppenheimer & Co.","Oppenheimer will receive 3.0% commission on gross proceeds; company also reimburses certain expenses.","Company has no obligation to sell any shares and may suspend or terminate the agreement at any time.","Shares will be issued under existing effective shelf registration statement (File No. 333-276814).","Offering is effective December 11, 2024; sales subject to company instructions and market conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190162,"accession_number":"0001104659-24-126761","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Annovis Bio appoints William Fricker as interim CFO effective December 4, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William Fricker, 61, appointed interim CFO; most recently CFO of NeuroTrauma Sciences (Dec 2023-Apr 2024).","Previously CFO at NRX Pharmaceuticals (2020-2021), taking it public, and CAO at Immunomedics (2018-2020) until sale to Gilead.","Fricker served as independent CFO contractor for biotech firms from 2021-2023; CPA (inactive), started career at PwC.","No related-party transactions; Fricker serves on contract basis without employment agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190161,"accession_number":"0001104659-24-116086","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annovis Bio Q3 net loss $0.97/share; FDA clears Phase 3 studies for buntanetap in early AD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA granted clearance for pivotal Phase 3 studies: a 6-month symptomatic and an 18-month disease-modifying trial in early Alzheimer's disease.","Cash and cash equivalents of $13.6M as of Nov 8, 2024; management says runway extends into Q1 2025 Phase 3 start.","Q3 total operating expenses were $4.4M, down sharply from $14.9M a year ago; R&D was $2.7M vs $13.9M.","Net loss per share (basic/diluted) was $0.97, compared to $1.63 in Q3 2023.","Filed three new combination-therapy patents for buntanetap with dulaglutide, sildenafil, or both."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190160,"accession_number":"0001104659-24-108360","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA Clears Annovis to Start Pivotal Phase 3 Alzheimer's Studies for Buntanetap","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA clearance to proceed with pivotal Phase 3 studies for buntanetap in early Alzheimer's disease.","Two trials: a 6-month symptomatic study and an 18-month disease-modifying study.","A well-executed 6-month trial may support NDA filing within one year of initiation.","No safety concerns raised; FDA confirmed liver enzymes, drug interactions, dose selection acceptable.","CEO Maria Maccecchini says trial initiation planned early 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206674,"accession_number":"0001104659-24-104002","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Annovis files three new patents for Buntanetap combinations with Trulicity and Viagra","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Patents cover Buntanetap + Trulicity (GLP-1), Buntanetap + Viagra (PDE5i), and triple combo.","Preclinical synergy data showed cognition in AD mouse models improved beyond healthy controls.","Combinations positioned for Phase 3 trials; Buntanetap completed Phase 3; Trulicity and Viagra are FDA-approved.","CEO: combination could restore and improve cognition, offering new hope in dementia fight.","Annovis expands IP portfolio for neurodegenerative disorders with these filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206673,"accession_number":"0001104659-24-089913","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annovis Bio Q2 net loss $0.44/share; cash $12.1M; AD & PD trial data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 net loss $0.44 per share vs $1.07 YoY; operating expenses $7.8M (R&D $5.8M, G&A $2.0M).","Cash $4.0M at June 30, 2024; increased to $12.1M as of Aug 14 via warrant exercises and ELOC.","Phase 2/3 AD study: 3.3-point ADAS-Cog11 improvement vs 0.3 placebo; effective in APOE4 carriers; no ARIA.","Phase 3 PD study: improvements in MDS-UPDRS and cognition; halted cognitive decline in all patients.","New crystalline buntanetap patent filed; FDA OK for phase 3 with crystal form; US patent for TBI; team expanded."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206672,"accession_number":"0001104659-24-086114","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Annovis Bio: buntanetap + GLP-1 agonist shows synergistic cognitive boost in AD mouse model","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Combination of buntanetap and dulaglutide (Trulicity) restored cognitive function beyond healthy controls in Alzheimer's mouse model.","Buntanetap alone restored to 100%, dulaglutide alone to 80%; combination showed 6-10x increase in efficacy.","GLP-1 agonist dulaglutide was chosen for its good blood-brain barrier permeability among single-chain peptides.","CEO Maria Maccecchini noted synergy could enhance treatment outcomes while minimizing side effects."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206671,"accession_number":"0001104659-24-080039","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA approves Annovis Bio's transition to new crystal form of Buntanetap for trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA approved transition to new crystalline form of Buntanetap for future clinical trials.","Company filed composition of matter patent for new form and provisional patent for manufacturing process in June 2024.","Comprehensive bridge studies in solvents and animals submitted to FDA.","FDA clearance allows a small single-dose bioavailability study in humans as part of transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206670,"accession_number":"0001104659-24-078937","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-07-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Warrant exercise raises $7M for Annovis Bio; 0.8M shares issued","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["0.8M November 2023 warrants exercised July 8-9, 2024 at $9.00 per share.","Gross proceeds of $7.0M from the exercise.","Approximately 0.8M shares of common stock issued.","Warrants were part of a prior offering from Nov 1, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206669,"accession_number":"0001104659-24-077093","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Buntanetap shows dose-dependent cognition gains; MDS-UPDRS improvements in PD Phase III","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Buntanetap at 20mg significantly improved MDS-UPDRS Part II, III, II+III, and Total in PD patients diagnosed >3 years.","In patients with mild dementia (MMSE 20-26), 20mg buntanetap showed significant cognitive improvement vs placebo.","PIGD subgroup also showed significant motor and non-motor improvements with buntanetap.","Safety profile consistent with prior AD data; no significant differences between early/advanced PD.","FDA feedback led to primary endpoint change; primary and secondary endpoints met in specified subgroups."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223864,"accession_number":"0001104659-24-071011","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Annovis Bio stockholders elect directors, approve equity plan amendment, ratify auditors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected; Michael Hoffman (3,856,586 for), Maria Maccecchini (3,888,261 for), Claudine Bruck, Reid McCarthy, Mark White.","Amendment to 2019 Equity Incentive Plan approved, adding 1,000,000 shares to the share reserve.","Ratification of Ernst & Young as independent auditor for FY2024 approved (7,214,275 for, 48,270 against).","66.10% of outstanding shares (7,278,396 shares) were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223863,"accession_number":"0001104659-24-070450","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-06-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Annovis Bio Buntanetap Phase II/III shows statistically significant efficacy in APOE4 Alzheimer's patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In early AD patients (MMSE 21-24), Buntanetap showed -3.3 point ADAS-Cog11 improvement vs baseline and -2.3 vs placebo.","APOE4 carriers on 15mg dose achieved -3.15 point improvement in ADAS-Cog11 scores.","Buntanetap had no ARIA or serious drug-related TEAEs; safety comparable in carriers and non-carriers.","Study included 159 APOE4 carriers (33 homozygotes) and 159 non-carriers.","Company plans 18-month Phase III trial in biomarker-positive early AD patients under FDA guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223862,"accession_number":"0001104659-24-068701","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Annovis Bio schedules investor webcast for June 11 to discuss Buntanetap progress","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Webcast scheduled for June 11, 2024 at 4:30pm ET; registration via Zoom link provided.","Topics include recent Buntanetap developments, upcoming clinical trial plans, and company progress.","Buntanetap is a late-stage drug candidate for Alzheimer's and Parkinson's diseases.","No specific data or results disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223861,"accession_number":"0001104659-24-063829","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Annovis Bio publishes Posiphen PK comparison across species in Biomolecules","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Publication in Biomolecules compares Posiphen pharmacokinetics across mouse, rat, dog, and human samples.","Posiphen reaches peak plasma concentration quickly, with high brain and CSF absorption.","Drug metabolizes into N1-norposiphen and N8-norposiphen; rapid clearance in plasma but longer retention in brain/CSF.","Absorption, distribution, metabolism, and excretion similar in healthy volunteers and Alzheimer's/Parkinson's patients.","CEO Maria Maccecchini states publication consolidates years of research for a holistic view of Posiphen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223860,"accession_number":"0001104659-24-060518","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annovis AD Phase II/III shows significant cognition improvement; PD topline due June 2024; Q1 cash $3.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 cash $3.1M vs $5.8M at Dec 31, 2023; runway into Q4 2024. Operating expenses $7.8M (R&D $6.5M, G&A $1.3M).","Phase II/III AD: ADAS-Cog 11 improvement 3.3 pts vs 0.3 for placebo at 3 months; plan 18-month Phase III trial.","PD Phase III unblinded; topline results expected June 2024; 523 patients randomized, 471 completed.","Net loss per share $0.10 basic, $0.72 diluted; includes $6.7M non-cash gain from warrant revaluation.","Filed patent application for buntanetap in neuropsychiatric disorders including autism, ADHD, depression."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223859,"accession_number":"0001104659-24-059315","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Annovis completes Phase III data unblinding for buntanetap; topline expected June","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Unblinding of Phase III study of buntanetap in early Parkinson's disease completed.","Topline efficacy data expected in June 2024.","Delay due to PK measurement error resolved; repeated analysis showed correct 33% blank samples.","Company confident in data integrity and ready for evaluation with FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223858,"accession_number":"0001104659-24-057525","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Annovis Bio CEO letter details Phase II/III AD data; will narrow enrollment to early-stage patients for next trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase II/III study in MMSE 21-24 patients: buntanetap showed ADAS-Cog11 improvement of -2.36 vs placebo at 3 months.","In moderate AD (MMSE 14-20), improvement was -0.65 vs placebo +1.79, indicating high placebo effect.","Next Phase III will prescreen for plasma AD biomarkers and enroll only early/mild AD (MMSE 21-28).","CEO states FDA will accept buntanetap for symptomatic relief and allow continuation for disease-modification study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223857,"accession_number":"0001558370-24-006534","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Annovis Bio closes common stock purchase agreement with equity line investor","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Closed transactions contemplated by Common Stock Purchase Agreement entered April 25, 2024.","Equity line investor purchased shares; no specific dollar amount or share count disclosed.","Loeb & Loeb LLP opinion on securities issuance filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223856,"accession_number":"0001104659-24-055838","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Annovis Bio CFO Henry Hagopian resigns; CEO Maria Maccecchini named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Henry Hagopian stepped down as CFO effective April 30, 2024, to pursue other opportunities; no disagreement with company.","CEO Maria Maccecchini appointed as interim principal financial officer effective May 1, 2024.","Severance includes 2 months base salary ($62,500) plus $3,000 medical/dental reimbursement, paid as lump sum.","Company accelerates vesting of 10,000 stock options and extends exercise period for certain options through Dec 31, 2024.","Hagopian signed a separation agreement with a general release of claims and non-disparagement obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223855,"accession_number":"0001104659-24-052471","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Annovis Bio enters equity line with Keystone Capital for up to 2.05M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company may sell up to 2,051,428 shares at market price, subject to 19.99% cap unless at-market.","Initial commitment shares: 10,181 delivered at signing; additional shares on days 90 and 180.","Proceeds will be used for working capital and general corporate purposes.","Investor Keystone Capital cannot engage in short sales or hedging during agreement term.","Fixed purchase limit: lower of 25,000 shares or $250,000; VWAP aggregate cap $10M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223854,"accession_number":"0001104659-24-042695","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-04-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Annovis Bio FY 2023 net loss $56.2M; cash $5.8M; PD Phase III completed, AD top-line data expected April","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2023 $22.2M vs $7.7M YoY; FY net loss $56.2M vs $25.3M.","Cash and equivalents $5.8M as of Dec 31, 2023, down from $28.4M.","R&D expenses $38.8M for FY 2023, up from $16.5M, driven by AD and PD trial costs.","PD Phase III completed with 471 patients; AD Phase II/III fully enrolled (353 patients); top-line efficacy data expected in April 2024.","Appointed Andrew Walsh as VP Finance in December 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243254,"accession_number":"0001104659-24-037958","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Annovis Bio closes $3M equity offering of 316,455 shares at $9.48/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $3,000,000 gross proceeds from sale of 316,455 common shares at $9.48 per share to an institutional investor.","Offering closed on March 22, 2024, under effective shelf registration statement on Form S-3 (No. 333-276814).","Securities Purchase Agreement signed March 21, 2024; shares issued directly without a placement agent.","Proceeds expected for general corporate purposes; dilution of ~3.2% based on prior outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243253,"accession_number":"0001104659-24-037406","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Annovis Bio raises $3M via registered direct offering of 316,455 shares at $9.48/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 316,455 common shares at $9.48 each for $3.0M gross proceeds under effective Form S-3 shelf registration.","30-day post-closing lock-up restricts new equity issuances, warrant amendments, registration filings, and variable-rate deals.","Closing contingent on NYSE listing of the offered shares; expected promptly after conditions satisfied.","Buyer may sell shares during pre-settlement period and remains unconditionally bound to purchase at closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243252,"accession_number":"0001104659-24-036742","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-03-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Annovis Bio completes data cleaning for phase II/III Alzheimer's study; topline data expected April 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Data cleaning completed for phase II/III trial of buntanetap in mild to moderate Alzheimer's disease.","Topline efficacy results expected in April 2024.","Study enrolled 353 patients; 327 completed; three doses (7.5, 15, 30 mg) vs placebo over 12 weeks.","All patients received standard of care in addition to buntanetap or placebo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243251,"accession_number":"0001104659-24-036331","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-03-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Annovis Bio closes $1.025M offering, issues 114,911 shares at $8.92","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $1,025,000 gross proceeds from a registered direct offering with an institutional investor.","Issued 114,911 shares of common stock at $8.92 per share.","Offering closed on March 19, 2024; shares issued under effective Form S-3 shelf registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243250,"accession_number":"0001104659-24-035082","cik":1477845,"company_name":"Annovis Bio, Inc.","ticker":"ANVS","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Annovis Bio enters securities purchase agreement for $1.025M common stock offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 114,911 shares at $8.92/share to institutional investor for gross proceeds of $1,025,000.","Issued under effective shelf registration statement on Form S-3 (333-276814) effective Feb 12, 2024.","Closing expected promptly after conditions satisfied, including NYSE listing of the shares.","30-day lock-up restricts additional equity issuances, warrant amendments, and variable rate transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":67156019.73134328,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}